Self-correction to the draft resolution of the General Meeting of Ryvu Therapeutics S.A. convened for September 19, 2022
Read More
Convening of the Extraordinary General Shareholders Meeting of Ryvu Therapeutics S.A.
Read More
Ryvu Therapeutics’ development plans for 2022-2024
Read More
Change of the date of publication of the periodic report for the first half of 2022
Read More
Conclusion of a financing agreement with the European Investment Bank
Read More
Changes in Ryvu’s Management Board
Read More
Information on a potential supply of shares in connection with the expiration of the lock-up period for shares under the Stock Grant Program
Read More
Execution of an exclusive license agreement with Exelixis, Inc. to develop novel STING agonist-based targeted cancer therapies
Read More
Shareholders controlling at least 5% of the votes at the General Shareholders Meeting of Ryvu Therapeutics S.A. convened on June 30, 2022
Read More
Resolutions adopted by the General Shareholders Meeting of Ryvu Therapeutics S.A.
Read More
Publication of the updated phase 1b clinical and preclinical data for RVU120 and phase 1/2 SEL24 (MEN1703)
Read More
Convening the Ordinary General Shareholders Meeting of Ryvu Therapeutics S.A.
Read More
Ryvu Therapeutics S.A. Q1 2022 Financial Report
Read More
New data from RVU120 and SEL24(MEN1703) programs to be presented at the EHA Hybrid Congress 2022
Read More
Ryvu Therapeutics to present recent RVU120 and SEL24 (MEN1703) data at ASCO 2022 Annual Meeting
Read More
Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR
Read More
Ryvu Therapeutics to present recent data from oncology programs at AACR 2022 Annual Meeting
Read More
Publication dates for periodic reports in 2022
Read More
Delivery of a lawsuit for payment in connection with the construction of the Research and Development Center
Read More
